Abvc Biopharma (ABVC) Exchange Rate Effect (2018 - 2026)
Abvc Biopharma's (ABVC) quarterly Exchange Rate Effect came in at $11355.0 in Q2 2026, up 122.43% on a YoY basis from $5104.9 in Q2 2025, and up 330.11% quarter-over-quarter from $2640.0 in Q1 2026.
Powered by 
Analysis
Abvc Biopharma (ABVC) Exchange Rate Effect (2018 - 2026) Analysis & Trends
Abvc Biopharma (ABVC) has reported Exchange Rate Effect for 9 consecutive years, with $11355.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Exchange Rate Effect rose 122.43% year-over-year to $11355.0; the trailing twelve-month figure through Jun 2026 stood at $78045.0 (up 311.41% YoY), and the FY2025 full-year result was $20264.0, up 182.41% from the prior year.
- Exchange Rate Effect grew to $11355.0 in Q2 2026 per ABVC's latest filing, from $2640.0 in the prior quarter.
- Across five years, Exchange Rate Effect topped out at $322300.0 in Q2 2023 and bottomed at -$308804.0 in Q1 2023.
- Historically, Exchange Rate Effect has averaged -$3085.7 across 5 years, with a median of $3022.5 in 2024.
- The sharpest annual moves came in 2022 and 2025: Exchange Rate Effect slumped 9162.27% in 2022, then soared 1421.41% in 2025.
- Over 5 years, Exchange Rate Effect stood at $219438.0 in 2022, then sank by 175.78% to -$166288.0 in 2023, then jumped by 102.08% to $3465.0 in 2024, then surged by 253.42% to $12246.0 in 2025, then slipped by 7.28% to $11355.0 in 2026.
- According to Business Quant data, Exchange Rate Effect over the past three periods registered $11355.0, $2640.0, and $12246.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -19.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | -3.70 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | -300,000.00 |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -2.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | -2.45 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -3.40 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 315,000.00 |
| 10 | Abvc Biopharma | 25.56 Mn | 25.56 Mn | - | 11,355.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 11,355.00 |
| Mar 31, 2026 | 2,640.00 |
| Dec 31, 2025 | 12,246.00 |
| Sep 30, 2025 | 51,804.00 |
| Jun 30, 2025 | -50,616.00 |
| Mar 31, 2025 | 6,830.00 |
| Dec 31, 2024 | 3,465.00 |
| Sep 30, 2024 | 3,405.00 |
| Jun 30, 2024 | -5,350.00 |
| Mar 31, 2024 | -26,109.00 |
| Dec 31, 2023 | -166,288.00 |
| Sep 30, 2023 | 154,917.00 |
| Jun 30, 2023 | 322,300.00 |
| Mar 31, 2023 | -308,804.00 |
| Dec 31, 2022 | 219,438.00 |
| Sep 30, 2022 | -195,745.00 |
| Jun 30, 2022 | -45,880.00 |
| Mar 31, 2022 | -45,150.00 |
| Dec 31, 2021 | -39,600.00 |
| Sep 30, 2021 | 2,160.00 |